Mennuni Marco G, Pagnotta Paolo A, Stefanini Giulio G
Cardiovascular Department, Humanitas Research Hospital, Rozzano, Milan, Italy.
Ann Biomed Eng. 2016 Feb;44(2):488-96. doi: 10.1007/s10439-015-1399-z. Epub 2015 Aug 12.
Percutaneous coronary interventions (PCI) were proposed in the late 1970s as an alternative to surgical coronary artery bypass grafting for the treatment of coronary artery disease. Important technological progress has been made since. Balloon angioplasty was replaced by bare metal stents, which allowed to permanently scaffold the coronary vessel avoiding acute recoil and abrupt occlusion. Thereafter, the introduction of early generation drug-eluting stents (DES) has significantly improved clinical outcomes, primarily by markedly reducing the risk of restenosis. New generation DES with thinner stent struts, novel durable or biodegradable polymer coatings, and new limus antiproliferative agents, have further improved upon the safety and efficacy profile of early generation DES. The present article aims to review the impact of technological advances on clinical outcomes in the field of PCI with coronary stents, and to provide a brief overview on clinical margins of improvement and unmet needs of available DES.
经皮冠状动脉介入治疗(PCI)于20世纪70年代末被提出,作为冠状动脉旁路移植术治疗冠状动脉疾病的替代方法。自那时以来取得了重要的技术进步。球囊血管成形术被裸金属支架所取代,裸金属支架能够永久性地支撑冠状动脉血管,避免急性回缩和突然闭塞。此后,早期药物洗脱支架(DES)的引入显著改善了临床结局,主要是通过显著降低再狭窄风险。具有更细支架小梁、新型耐用或可生物降解聚合物涂层以及新型雷帕霉素抗增殖剂的新一代DES,进一步改善了早期DES的安全性和有效性。本文旨在综述技术进步对冠状动脉支架PCI领域临床结局的影响,并简要概述现有DES的临床改善幅度和未满足的需求。